Figure 2
From: Development of anti-thrombotic vaccine against human S100A9 in rhesus monkey
Production of antibody against S100A9 by vaccination. (A,B) The antibody titers against the epitope in mice (A) and monkeys (B). (A) The epitopes in C-terminus (97–106 aa and 104–113 aa) are more effective than that in N-terminus (2–11 aa). Data represent the mean ± SEM of n = 3 in each group. (B) Antibody titers before (left bar) and after (right bar) the vaccine are presented. All monkeys were successfully vaccinated. (C) Western blot analysis for production of antibodies specific for recombinant human S100A9 protein (14 kDa) in No. 4 monkey. The serum samples from pre-vaccination (Pre) and post-vaccination (Post) were examined to determine whether they included antibodies that recognize recombinant S100A9 protein. The commercially available anti-S100A9 antibody (PC) or IgG purified from another normal monkey (NC) was used as a positive control or a negative control, respectively.
